| Name | Title | Contact Details |
|---|---|---|
Vinay Bhupathy |
General Counsel | Profile |
Talis is developing a new class of diagnostic platform to enable rapid, high-complexity testing across a wide range of healthcare settings.
Boston Biochem is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.
St. Mary's Janesville Hospital is a Janesville, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.